Regorafenib Post-marketing Surveillance in Japan

Status:
Active, not recruiting

Trial end date:
2022-01-31

Target enrollment:

Participant gender:

The objective of this study is to assess safety and effectiveness of Regorafenib using in real clinical practice

Bayer